

TARGETED GENETICS CORP /WA/  
Form 8-K  
July 30, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 26, 2007**

**Targeted Genetics Corporation**  
(Exact name of registrant as specified in its charter)

<b>Washington</b> (State or other jurisdiction of incorporation)	<b>0-23930</b> (Commission File Number)	<b>91-1549568</b> (IRS Employer Identification No.)
<b>1100 Olive Way, Suite 100, Seattle, Washington</b> (Address of principal executive offices)		<b>98101</b> (Zip Code)
Registrant's telephone number, including area code		<b>(206) 623-7612</b>

**Not Applicable**

---

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01 Other Events.**

On July 26, 2007, Targeted Genetics Corporation announced an update on its development program of tgAAC94, an investigational therapy for the treatment of inflammatory arthritis, and its previous announcement of July 24 that the company and the United States Food and Drug Administration stopped the trial as a precautionary measure after the occurrence of a Serious Adverse Event in one subject.

A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99.1 Press Release of Targeted Genetics Corporation dated July 26, 2007

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

By:

/s/ H. STEWART PARKER

H. Stewart Parker  
President and Chief Executive Officer

Dated: July 30, 2007

---

**INDEX TO EXHIBITS**

99.1 Press Release of Targeted Genetics Corporation dated July 26, 2007